Product category:
Clinical chemistry analysis
News Release from: Bio-Rad Laboratories | Subject: BioPlex 2200
Edited by the Laboratorytalk Editorial
Team on 12 January 2007
Agreement for anti-CCP rheumatoid
arthritis test
Bio-Rad Laboratories and Axis-Shield have signed an agreement that gives Bio-Rad access to Axis-Shield's test for the early detection of rheumatoid arthritis
The assay, which will run on Bio-Rad's BioPlex 2200 system, tests for anti-CCP (anti-cyclic citrullinated peptide antibodies) The anti-CCP assay is a significant recent development in the early diagnosis of rheumatoid arthritis, facilitating improved management of this widespread and debilitating condition
This article was originally published on Laboratorytalk on 17 May 2006 at 8.00am (UK)
Related stories
FDA OK for autoimmune decision support software
Bio-Rad gains marketing clearance from the US FDA for its Medical Decision Support Software (MDSS) designed for use with the company's FDA cleared BioPlex 2200 ANA Screen and BioPlex 2200 system
Epstein Barr virus kits for use on BioPlex 2200
Bio-Rad Laboratories has launched two Epstein Barr Virus (EBV) kits for use on its BioPlex 2200 system, a diagnostic platform that employs multiplexing technology to s for multiple disease markers
"The ability to incorporate an anti-CCP test as part of a rheumatoid arthritis panel will add significantly to our growing menu of autoimmune tests on the BioPlex 2200 system," said John Goetz, Bio-Rad vice president and group manager of clinical diagnostics.
"As the first and only fully automated, random access multiplex testing platform, the BioPlex 2200 system is ideally suited as a platform for multi-marker autoimmune testing that includes rheumatoid arthritis".
"We are very pleased that our important patented assay for anti-CCP will be added to the menu of this versatile platform," said Svein Lien, Axis-Shield CEO.
"We have a history of successful collaboration with Bio-Rad, which is a highly respected and pioneering organisation in life sciences and a major player in human diagnostic testing and believe the BioPlex 2200 system will add an extra dimension to anti-CCP marketing".
The BioPlex 2200 system is a fully automated, random access multiplex testing platform that can deliver up to 2200 results per hour.
The system currently includes a panel of assays targeting autoimmune diagnostics. Request a free brochure from Bio-Rad Laboratories ...
• Bio-Rad Laboratories: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
